Lifelong low LDL-C levels key to preventing cardiovascular disease

FHS
July 9, 2024
2:00 am

Research shows maintaining low LDL-C levels over time reduces plaque buildup and lowers ASCVD risk by slowing atherosclerosis progression.

Takeda’s FRUZAQLA gains approval in Japan for colorectal cancer

FRUZAQLA is intended for patients with CRC that has progressed following chemotherapy. Credit: SewCreamStudio/Shutterstock. Takeda has secured approval from the Japanese Ministry of Health, Labour

September 24, 2024

Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients

Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that

March 7, 2024

PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares – Biotech Investments

PharmaSGP Holding SE / Key word(s): Share Buyback PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to

September 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.